| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 526 | 2019 |
| Discovery of piperlongumine as a potential novel lead for the development of senolytic agents Y Wang, J Chang, X Liu, X Zhang, S Zhang, X Zhang, D Zhou, G Zheng Aging (Albany NY) 8 (11), 2915, 2016 | 274 | 2016 |
| Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity Y He, X Zhang, J Chang, HN Kim, P Zhang, Y Wang, S Khan, X Liu, ... Nature communications 11 (1), 1996, 2020 | 224 | 2020 |
| PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics S Khan, Y He, X Zhang, Y Yuan, S Pu, Q Kong, G Zheng, D Zhou Oncogene 39 (26), 4909-4924, 2020 | 206 | 2020 |
| Oxidation resistance 1 is a novel senolytic target X Zhang, S Zhang, X Liu, Y Wang, J Chang, X Zhang, SG Mackintosh, ... Aging cell 17 (4), e12780, 2018 | 119 | 2018 |
| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... Nature communications 12 (1), 6896, 2021 | 112 | 2021 |
| DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas Y He, R Koch, V Budamagunta, P Zhang, X Zhang, S Khan, D Thummuri, ... Journal of hematology & oncology 13, 1-13, 2020 | 101 | 2020 |
| Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies Y He, S Khan, Z Huo, D Lv, X Zhang, X Liu, Y Yuan, R Hromas, M Xu, ... Journal of Hematology & Oncology 13, 1-24, 2020 | 98 | 2020 |
| Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs Y Xiao, J Wang, LY Zhao, X Chen, G Zheng, X Zhang, D Liao Chemical Communications 56 (68), 9866-9869, 2020 | 94 | 2020 |
| Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors X Zhang, Y Kong, J Zhang, M Su, Y Zhou, Y Zang, J Li, Y Chen, Y Fang, ... European journal of medicinal chemistry 95, 127-135, 2015 | 93 | 2015 |
| Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity Y He, W Li, D Lv, X Zhang, X Zhang, YT Ortiz, V Budamagunta, J Campisi, ... Aging cell 19 (3), e13117, 2020 | 91 | 2020 |
| Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity X Zhang, D Thummuri, X Liu, W Hu, P Zhang, S Khan, Y Yuan, D Zhou, ... European journal of medicinal chemistry 192, 112186, 2020 | 86 | 2020 |
| The discovery of colchicine-SAHA hybrids as a new class of antitumor agents X Zhang, J Zhang, L Tong, Y Luo, M Su, Y Zang, J Li, W Lu, Y Chen Bioorganic & medicinal chemistry 21 (11), 3240-3244, 2013 | 82 | 2013 |
| Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL X Zhang, D Thummuri, Y He, X Liu, P Zhang, D Zhou, G Zheng Chemical Communications 55 (98), 14765-14768, 2019 | 76 | 2019 |
| Senolytic activity of piperlongumine analogues: synthesis and biological evaluation X Liu, Y Wang, X Zhang, Z Gao, S Zhang, P Shi, X Zhang, L Song, ... Bioorganic & medicinal chemistry 26 (14), 3925-3938, 2018 | 65 | 2018 |
| Assays and technologies for developing proteolysis targeting chimera degraders X Liu, X Zhang, D Lv, Y Yuan, G Zheng, D Zhou Future Medicinal Chemistry 12 (12), 1155-1179, 2020 | 58 | 2020 |
| Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines X Zhang, Y He, P Zhang, V Budamagunta, D Lv, D Thummuri, Y Yang, ... European journal of medicinal chemistry 199, 112397, 2020 | 54 | 2020 |
| The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase X Zhang, B Bao, X Yu, L Tong, Y Luo, Q Huang, M Su, L Sheng, J Li, ... Bioorganic & medicinal chemistry 21 (22), 6981-6995, 2013 | 50 | 2013 |
| Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216 D Thummuri, S Khan, PW Underwood, P Zhang, J Wiegand, X Zhang, ... Molecular cancer therapeutics 21 (1), 184-192, 2022 | 45 | 2022 |
| Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells R Kolb, U De, S Khan, Y Luo, MC Kim, H Yu, C Wu, J Mo, X Zhang, ... Nature communications 12 (1), 1281, 2021 | 44 | 2021 |
Guangrong ZhengProfessor, University of FloridaVerified email at cop.ufl.edu